Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
construction
release_alert
Scholars@Duke will be down for maintenance for approximately one hour starting Tuesday, 11/11 @1pm ET
cancel
Georgia Marie Beasley
Associate Professor of Surgery
Surgical Oncology
georgia.beasley@duke.edu
Erwin Rd, Durham, NC 27710
Dept of Surgery, Durham, NC 27710
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
Leadership & Clinical Positions
Professional Training and Employment
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti
Clinical Trial
Principal Investigator ·
Awarded by Replimune, Inc. ·
2024 - 2029
Duke Research Training Program in Surgical Oncology
Inst. Training Prgm or CME
Mentor ·
Awarded by National Cancer Institute ·
2024 - 2029
An Open-Label, Randomized, Controlled Multi-Center Study of the Efficacy of Daromun (L19IL2+L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Pati
Clinical Trial
Principal Investigator ·
Awarded by Philogen S.p.A ·
2022 - 2027
U.S. Retrospective Collaborative Study of Melanoma Patients receiving Immune Checkpoint Therapy; "Real World Study"
Research
Principal Investigator ·
Awarded by Bristol-Myers Squibb Company ·
2024 - 2027
A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients
Clinical Trial
Principal Investigator ·
Awarded by SkylineDx ·
2022 - 2027
Improving decision-making for older adults with melanoma
Research
Collaborator ·
Awarded by National Institutes of Health ·
2024 - 2026
Detecting missed metastases from nominally early-stage melanomas with pump-probe microscopy
Research
Co Investigator ·
Awarded by United States Army Medical Research Acquisition Activity ·
2023 - 2026
Beyond tumor staging: measuring immune status at initial diagnosis to detect and prevent melanoma recurrence
Research
Principal Investigator ·
Awarded by Department of Defense ·
2023 - 2026
The frequency and function of Type 3 Innate Lymphoid Cells regulates the melanoma tumor microenvironment
Fellowship
Co-Mentor ·
Awarded by National Cancer Institute ·
2024 - 2026
Training Program in Bioinformatics at the Intersection of Cancer Immunology and Microbiome
Research
Collaborator ·
Awarded by National Cancer Institute ·
2020 - 2026
Replimune RPL-001-16
Clinical Trial
Principal Investigator ·
Awarded by Replimune Group, INC ·
2021 - 2026
Improving Accuracy of Next-Generation Microscopy for Early Stage Metastatic Melanoma Detection
Research
Collaborator ·
Awarded by National Cancer Institute ·
2024 - 2025
Checkmate CMP-001-010
Clinical Trial
Principal Investigator ·
Awarded by Checkmate Pharmaceuticals ·
2020 - 2025
Overcoming Anti-PD-1 Resistance in Melanoma by Targeting Immunologic Mediators of the Gli2 Pathway
Research
Collaborator ·
Awarded by The Melanoma Research Foundation ·
2022 - 2025
Modulation of tumor microenvironment to hinder cancer progression and therapeutic resistance
Research
Co Investigator ·
Awarded by Department of Defense ·
2022 - 2025
Investigating the Role of a Novel Dendritic Cell Subset within Sentinel Lymph Node Tissues in Immune Evasion and Melanomagenesis
Research
Co Investigator ·
Awarded by Department of Defense ·
2021 - 2025
Clinical Biomarker Study of the Tumor NLRP3 Inflammasome and its Role in Anti-PD-1 Immunotherapy Resistance
Research
Co Investigator ·
Awarded by Conquer Cancer Foundation ·
2021 - 2025
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients with Hepatic Dominant Ocular Melanoma
Clinical Trial
Principal Investigator ·
Awarded by Delcath Systems, Inc. ·
2022 - 2025
CMP-001-011
Clinical Trial
Principal Investigator ·
Awarded by Checkmate Pharmaceuticals ·
2020 - 2025
PVSRIPO in melanoma
Research
Principal Investigator ·
Awarded by National Cancer Institute ·
2020 - 2025
OMS-I103 / PICSES
Clinical Trial
Principal Investigator ·
Awarded by OncoSec Medical ·
2020 - 2024
A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
Clinical Trial
Principal Investigator ·
Awarded by Delcath Systems, Inc. ·
2016 - 2023
A Phase I trial of PVSRIPO for Patients with Unresectable Melanoma
Clinical Trial
Principal Investigator ·
Awarded by Istari Oncology ·
2018 - 2022
Tumor draining lymph node B cells as regulators of melanoma progression
Research
Co Investigator ·
Awarded by Department of Defense ·
2020 - 2021
Comprehensive immunologic profiling of the sentinel node to optimize care for patients with melanoma
Research
Principal Investigator ·
Awarded by Society of Surgical Oncology ·
2019 - 2020
